Preliminary Report of the Ad-hoc Expert Consultation on Risk Assessment of Microbiological Hazards in Food and Related Matters
Document not in the Codex Step Procedure.
WHO/FAO are the lead organizations in the development of this document.
FDA has the lead for the U.S. Bob Buchanan provides the technical lead.
Rationale for Work. Provides an international risk assessment for selected pathogen/commodity combinations of key international public health significance.
Expected FDA work activities for 2000. Attend WHO/FAO Ad-Hoc Expert Consultation on the specific microbiological risk assessments. Review microbiological risk assessments presented to CCFH. Provide lead on the document for public meetings. Prepare and present U.S. position on the document at the 33rd Session of CCFH. Recommend future microbiological risk assessment priorities for the Ad-Hoc Expert Consultations.
Proposed Draft Code of Hygienic Practice for the Primary Production, Harvesting and Packaging of Fresh Fruits and Vegetables
Document is at Step 3 of the Codex procedure.
Canada is the lead country for the development of this Code.
FDA has the lead for the U.S. Joyce Saltsman and Michelle Smith provide the technical lead.
Rationale for work: Provide an international set of good hygienic production and processing practices for fresh produce.
Expected FDA work activities for 2000: Participate in international working group on document; prepare country comments on document; provide lead on the document for public meetings; prepare and present U.S. position on the document at the 33rd Session of CCFH.
Proposed Draft Code of Hygienic Practice for Pre-Cut Fruits and Vegetables,
Document is at Step 3 of the Codex procedure.
France is the lead country for the development of this Code.
FDA has the lead for the U.S. Joyce Saltsman and Michelle Smith provide the technical lead.
Rationale for work: Provide an international set of good hygienic production and processing practices for pre-cut fruits and vegetables.
Expected FDA work activities for 2000: Participate in international working group on document; provide lead on the document for public meetings; prepare and present U.S. position on the document at the 33rd Session of CCFH.
Guidelines and Principles for the Conduct of Microbiological Risk Management
Document is at Step 3 of the Codex procedure.
France is the lead country for the development of this document.
FDA has the lead for the U.S. Mike Wehr/Bob Buchanan provide the technical lead.
Rationale for work: Provide internationally recognized guidelines on how countries (including the United States) should undertake the process of microbiological risk management.
Expected FDA work activities for 2000: Participate in an international working group to develop the document; provide lead on the document for public meetings provide country comments on document; prepare and present U.S. position on the document at the 33rd Session of CCFH.
Proposed Draft Code of Hygienic Practice for Milk and Milk Products
Document is at Step 3 of the Codex procedure.
U.S. is the lead country for the development of this Code.
FDA has the lead for the U.S. Jack Mowbray provides the technical lead.
Rationale for work: Provide an international set of good hygienic production and processing practices for milk and milk products.
Expected FDA work activities for 2000-. Revise document based on 1999 CCFH meeting discussion, country comments and effort of an international working group. Chair international working group on development of the document; revise document based on working group output; prepare country comments on document; provide lead on the document for public meetings; prepare draft U.S. position on document, lead discussion on document at 33rd Session. Prepare and present U.S. position on the document at the 33rd Session of CCFH. Plan for 2001 international working group meeting.
Discussion Paper on Proposed Draft Guidelines on the Hygienic Reuse of Processing Water in Food Plants
Document at Step 3 of the Codex procedure.
The U.S. is the lead country for the development of this document.
USDA FSIS is the lead for the U.S. FDA Representative is George Hoskins, Office of Seafood.
Rationale for work: Provide international guidance on how recycled water can be hygienically and safely used in food production.
Expected FDA work activities for 2000: Assist USDA in revising document; provide country comments on discussion paper; assist in development of the draft U.S. position on document for 33rd Session. Present U.S. position on document at 33rd Session.
Discussion Paper on Draft Recommendations for the Control of Listeria in Foods
Document is a Discussion Document
Germany is the lead country for the development of this document
FDA has the lead for the U.S. Richard Whiting and Anthony Hitchins provide the technical lead.
Rationale for the work: Provide risk management guidance on the control of Listeria monocytogenes in foods.
Expected FDA work output for 2000: Review revised paper and prepare country comments; provide lead on the document for public meetings; prepare and present U.S. position on the document at the 33rd Session of CCFH.
Discussion Paper on the Development of Risk-Based Guidance for the Use of HACCP-like Systems in Small Business
Document remains a Discussion Paper.
The Netherlands is the lead country for the development of this document.
FDA has the lead for the U.S. Jeffery Brown, Division of HACCP Programs provides the technical lead.
Rationale for work: Develop guidance on how HACCP programs should be implemented in small businesses.
Expected FDA work output for 2000: Participate in the Working Group to revise the document. Provide lead on the document for public meetings. Prepare and present U.S. position on the document at the 33rd Session of CCFH.
Discussion Paper on Antimicrobial Resistance in Bacteria in Food
Document remains a discussion paper.
Denmark is the lead country for the development of this document.
Lead for the U.S: FDA CVM
Rationale for work: Develop a risk profile for the existence of antimicrobial resistant organisms in foods.
Expected FDA work output for 2000: Assist in the preparation of revised discussion paper; prepare country comments on paper; provide lead on the document for public meetings; prepare and present U.S. position on the document at the 33rd Session of CCFH.
Discussion Paper on Validation of Food Hygienic Control Measures
New Work for the Committee; Discussion Paper to be developed.
United States is the lead country for the development of this document
Lead for the U.S. FDA CFSAN. Mike Wehr/George Jackson will provide the technical lead.
Rationale for the work: Develop international guidelines to permit countries to demonstrate that specific food hygiene control measures meet a given level of public health protection for a specific hazard in a particular food.
Expected FDA work output for 2000: Prepare Discussion Paper; provide lead on the document for public meetings; prepare and present U.S. position on the document at the 33rd Session of CCFH; lead discussion on Paper at 33rd Session of CCFH.
Discussion Paper on Objectionable Matter in Food
New Work for the Committee; Discussion Paper to be developed.
United States is the lead country for the development of this document
Lead for the U.S. FDA CFSAN. Alan Olsen will provide the technical lead.
Rationale for the work: Develop international guidelines for countries to scientifically evaluate the presence of objectionable material (extraneous material/filth) in food.
Expected FDA work output for 2000: Prepare Discussion Paper; provide lead on the document for public meetings. prepare and present U.S. position on the document at the 33rd Session of CCFH; lead discussion on document at 33rd Session of CCFH.
Discussion Paper on Priorities for the Revision of Codex Codes of Hygienic Practice
Document remains a Discussion Paper.
Australia is the lead country for the development of this document
FDA has the lead for the U.S. Mike Wehr provides the technical lead.
Rationale for the work: Determine which older Codex Codes of Hygienic Practice need to be revised, the priorities for revision, which can be combined in the revision process, and which can be discontinued.
Expected FDA work output for 2000: Review Discussion Paper; provide lead on the document for public meetings; prepare and present U.S. position on Paper.
